$GRDN

Guardian Pharmacy: Q2 Earnings Snapshot

Guardian Pharmacy Services Inc. (GRDN) reported Q2 profit of $21.9 million, or 34 cents per share. Adjusted earnings were 29 cents versus a Zacks-surveyed analyst average of 26 cents. Revenue was $351.8 million. The company forecast full-year revenue of $1.43 billion to $1.45 billion.

Original reporting
Published Aug 7, 2026, 1:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 1:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$GRDN
Bullish
medium confidence
Mentioned
$GRDN
Relevance
8/10
alphai data visualization · based on local3news.com
Decision brief

The 30-second read

$GRDNBullishMed
01

Why it matters

The company’s Q2 results beat analyst expectations and it provided a specific full-year revenue range, which can drive estimate revisions and near-term trading in GRDN.

02

Market read

This is a direct earnings-and-guidance update for GRDN with a quantified beat and quantified revenue outlook.

03

What to watch

The article does not provide segment margins, cash flow, or detailed drivers of the beat, so traders may need to verify whether the outperformance is recurring or driven by one-time items.

Relevance 8/10Novelty 7/10Timing: reported Q2 results and full-year revenue outlook on 2026-08-07

Background

Guardian Pharmacy Services is a provider of pharmacy services to long-term care facilities.

Company-level read

Ticker impact

$GRDNBullishMedium confidence
Context

Guardian Pharmacy Services reported Q2 profit of $21.9M, EPS 34 cents, and raised full-year revenue guidance to $1.43B-$1.45B.

Expected impact

Likely near-term positive bias as the beat versus the 26-cent consensus and the stated full-year revenue range can support estimates and sentiment.

Evidence & confidence

The article discloses both quarterly results versus expectations and a specific full-year revenue outlook range, which are direct inputs to valuation and near-term positioning.

Market effects

Adds incremental datapoint for pharmacy services providers serving long-term care facilities, but no direct sector-wide reset is indicated.

Limited, as the disclosure is company-specific with no broader regional policy or demand signal.

Low, as the company is not presented as having global exposure or cross-border catalysts.

Counterpoint

A single-quarter EPS beat may not translate into sustained upside if margins or demand trends deteriorate, and the guidance range could still be conservative versus what the market wants.

Key entities

  • Guardian Pharmacy Services Inc.

    Reported Q2 profit and EPS, beat consensus, and guided full-year revenue to $1.43B-$1.45B.

Related articles

$GRDNHigh

Guardian Pharmacy Services, Inc. (GRDN): Results of Operations and Financial Condition

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d160709dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”)

$CATMedAI 8/10

Critical Minerals: How Data Centres are Boosting Caterpillar

Caterpillar shares rose about 12% on 4 August after its Q2 results beat analyst expectations. The company reported revenue of $20.54bn, up 24% year on year, and adjusted EPS of $8.17 versus $6.20 expected. Operating profit was $4.3bn. Order backlog reached $72.1bn, up 92%, supporting construction and power demand tied to data centres.

$LEEMed

Lee Enterprises, Incorporated Q3 2026 Earnings Call Summary

Lee Enterprises reported Q3 2026 progress toward a digital-first model, saying digital revenue was 57% of total revenue. It cited a 15% cash cost reduction and fifth straight quarter of comparable adjusted EBITDA growth, raising full-year adjusted EBITDA guidance to 22% to 28%. The company expects about $18M annual interest savings, positive net income of $5.2M, and plans debt paydown using excess cash and non-core asset sales.

$LNGMed

Cheniere Energy, Inc. Q2 2026 Earnings Call Summary

Cheniere Energy’s Q2 2026 call cited production outperformance and faster Corpus Christi Stage 3 startup for a second guidance raise. Full-year 2026 adjusted EBITDA guidance was revised to $7.9B-$8.4B. Management expects Sabine Pass Phase 1 FID by early 2027, targets dividend growth of at least 10% annually, and issued $1.75B dual-tranche bonds extending maturities to 2056.

$MARAMed

Marathon Digital Holdings, Inc. Q2 2026 Earnings Call Summary

Marathon Digital Holdings (MARA) discussed its Q2 2026 shift from Bitcoin mining to power-centric AI infrastructure. Management said it aims to expand energized power capacity to 4.8 GW via Matagorda and the pending Long Ridge deal, projected to add about $144 million annualized EBITDA. MARA reported a $611 million net loss, including a $343 million unrealized fair value adjustment tied to a 28% lower Bitcoin average price.